SOURCE: Matinas BioPharma Holdings, Inc.

November 06, 2013 08:00 ET

Matinas Biopharma Establishes Corporate Headquarters in New Jersey

BEDMINSTER, NJ--(Marketwired - November 06, 2013) - Matinas BioPharma Holdings, Inc., an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular conditions, announced today that the Company has established its corporate headquarters and opened an office in Bedminster, New Jersey. 

Effective immediately, Matinas BioPharma's Corporate Headquarters are located at:
1545 Route 206
Bedminster, NJ 07921

Matinas BioPharma recently closed a $15 million financing, which positioned the Company to begin advancing the development of its innovative omega-3 lead product candidate, MAT9001, for the treatment of severe hypertriglyceridemia and mixed dyslipidemia.

Roelof Rongen, Chief Executive Officer of Matinas BioPharma, stated, "Establishing our Headquarters in New Jersey was an important decision for the Company. We believe this strategically positions us very well to have access to great talent and the financial and pharmaceutical communities."

About MAT9001
Matinas BioPharma is developing MAT9001 for therapeutic applications, with severe hypertriglyceridemia (TG > 500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/d with concomitant statin therapy) as the lead indications. Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration and conduct a human study in the first half of 2014. Assuming positive data from this study, Matinas BioPharma anticipates commencing the first of its pivotal Phase 3 registration studies in 2014. The Company believes that the composition of MAT9001 represents a significantly differentiated lipid profile, providing unique clinical benefits.

About Matinas BioPharma
Matinas BioPharma Holdings, Inc. is an early stage privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of cardiovascular conditions. The Company's lead product candidate, MAT9001, is designed for treatment of severe hypertriglyceridemia (TG > 500 mg/dl) and mixed dyslipidemia (TG 200-499 mg/dl while on statin therapy). The Matinas BioPharma management team brings a cumulative multi-decade omega-3 pharmaceutical experience to the Company, providing a unique perspective and capability for the development of the next generation of omega-3-fatty acid-based pharmaceutical products.

For more information, please visit www.matinasbiopharma.com.

Forward Looking Statements: This release contains "forward-looking statements", including those related to the Company's strategic focus and the future development MAT9001. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Investor and Media Contact
    Jenene Thomas
    Investor Relations and Corporate Communications Advisor
    Jenene Thomas Communications, LLC
    Phone: +1 (908) 938-1475 
    Email: Jthomas@matinasbiopharma.com